Glancy Binkow & Goldberg LLP Announces Investigation of Synovis Life Technologies, Inc.
December 14 2011 - 1:39PM
Business Wire
Glancy Binkow & Goldberg LLP announces that it is
investigating potential claims against the Board of Directors of
Synovis Life Technologies, Inc. (“Synovis” or the “Company”)
(NASDAQ: SYNO) related to the proposed acquisition of the Company
by Baxter International, Inc. The transaction is valued at
approximately $325 million or $28 per share.
The investigation concerns whether the Board of Directors of
Synovis breached their fiduciary duties to stockholders by failing
to adequately shop the Company before agreeing to enter into the
proposed transaction, and whether the Company has disclosed all
material information to shareholders about the transaction. The
Company has seen substantial recent growth. It’s share price has
sky rocketed from $14.99 on January 31, 2011 to $21.19 on April 5,
2011.
If you are a shareholder of Synovis, if you have information or
would like to learn more about these claims, or if you wish to
discuss these matters or have any questions concerning this
announcement or your rights or interests with respect to these
matters, please contact Louis Boyarsky, Esquire, Glancy Binkow
& Goldberg LLP, 1925 Century Park East, Suite 2100, Los
Angeles, CA 90067, by telephone at (310) 201-9150 or Toll Free at
(888) 773-9224 or by email to shareholders@glancylaw.com.
This press release may be considered Attorney Advertising in
some jurisdictions under the applicable law and ethical rules.
Synovis Life Technologies, Inc. (MM) (NASDAQ:SYNO)
Historical Stock Chart
From May 2024 to Jun 2024
Synovis Life Technologies, Inc. (MM) (NASDAQ:SYNO)
Historical Stock Chart
From Jun 2023 to Jun 2024
Real-Time news about Synovis Life Technologies, Inc. (MM) (NASDAQ): 0 recent articles
More Glancy Binkow & Goldberg LLP News Articles